27 November 2019

Verona Pharma plc: Grant of Options to PDMR

LONDON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that, on November 26, 2019, it granted 500,000 options to purchase ordinary shares of £0.05 each (the “Ordinary Shares”) to its CEO, Dr. Jan-Anders Karlsson, under and in accordance with Verona Pharma’s 2017 Incentive Award Plan (which is set out in Verona Pharma’s 2018 annual report and 20-F) (the “Options”).

The Options have an exercise price of £0.445 per Ordinary Share, being the closing mid-market price on November 25, 2019. The Options will vest over two different periods following the grant date:  250,000 of the options will vest in three substantially equal annual instalments and the other half of the Options will vest in four substantially equal annual instalments.

Further information is provided below in accordance with the requirements of the EU Market Abuse Regulation.

For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officerinfo@veronapharma.com
Victoria Stewart, Director of Communications 
  
N+1 Singer
(Nominated Adviser and UK Broker)
Tel: +44 (0)20 3283 4200
Aubrey Powell 
Mia Gardner (Corporate Broking) 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1 Details of the person discharging managerial responsibilities / person closely associated
       
a) Name Dr. Jan-Anders Karlsson
       
2 Reason for the notification  
       
a) Position/status Chief Executive Officer
       
b) Initial notification /Amendment Initial Notification
       
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
       
a) Name Verona Pharma plc
       
b) Legal Entity Identifier 213800EVI6O6J3TIAL06
       
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
       
a) Description of the financial instrument, type of instrument Ordinary shares of 5p each
       
  Identification code ISIN Code: GB00BYW2KH80
       
b) Nature of the transaction Issue of options over Ordinary Shares
       
c) Price(s) and volume(s)    
    Price(s)Volume(s) 
       
    Exercise Price:  £0.445500,000 Options over Ordinary Shares 
       
       
d) - Aggregated information

 
- Aggregated volume


- Price
 N/a (single transaction)
     
e) Date of the transaction 26 November 2019
       
f) Place of the transaction Off market
       

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Victoria Stewart, Director of Communications
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Brough Ransom /Mia Gardner (Corporate Broking)
Tel: +44 (0)20 3283 4200

 

 

Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Annemarieke Ezendam
Hollie Vile
Tel: +44 (0) 203 950 9144
verona@optimumcomms.com

Argot Partners (Investor enquiries)
Stephanie Marks
Tel. +1 646 644 9590
verona@argotpartners.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us